Aktienanalyse zu Viking Therapeutics Inc (VKTX)VKTXViking Therapeutics Inc

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Viking Therapeutics Inc (VKTX) is currently trading at $25.17, which is significantly below the analyst price targets of $85 and $120 from Truist and Oppenheimer, respectively. However, the stock has shown a 28.94% year-to-date decline, and the RSI is at a low 30.3, indicating oversold conditions. The company is facing substantial net losses, projected to reach -$158 million in Q1 2026, which raises concerns about its financial stability. The upcoming Phase 3 trials for VK2735 could be a potential catalyst for recovery, but the risks associated with competition and ongoing losses suggest a cautious approach. Given these factors, it may be prudent to hold VKTX for now and reassess after the trial results.

3 analysts cover VKTX: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 97.00.